Patient Drug Leaflets Should Consolidate Side Effect Info, Research Suggests
Executive Summary
Patient drug information leaflets that display side effect information in special areas to grab patients' attention may actually make it more difficult for patients to remember essential drug information, a cognition researcher told FDA July 19.
You may also be interested in...
“Cognitively Accessible” Rx Labeling Tested By FDA Risk Cmte. Member Day
"Cognitively accessible" prescription drug labeling could reduce medical errors by as much as 80%, according to a forthcoming study by FDA drug safety advisory committee member Ruth Day, PhD
“Cognitively Accessible” Rx Labeling Tested By FDA Risk Cmte. Member Day
"Cognitively accessible" prescription drug labeling could reduce medical errors by as much as 80%, according to a forthcoming study by FDA drug safety advisory committee member Ruth Day, PhD
FDA Adverse Event Draft Guidance Would Restrict "Well Tolerated" Claims
FDA would restrict the use of nonspecific safety claims such as "well tolerated" under its draft guidance on adverse event labeling.